In the Destiny-Lung01 trial, which led to the breakthrough therapy designation of trastuzumab-deruxtecan for HER2-mutant NSCLC, HER2 mutation status was determined again by a CLIA standards local NGS method or equivalent and then centrally confirmed with the OncomineTM Dx Target Test (Thermo Fisher Scientific, Waltham, MA, USA). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.